血管生成与鼻咽癌靶向治疗进展  

ngiogenesis and Targeted Therapy for Nasopharyngeal Cancer

作　　者：刘芳贤[1] LIU Fang-xian(Deputy chief physician Affiliated Hospital of Guilin Medical College 541000,China)

机构地区：[1]桂林医学院附属医院,广西桂林541000

出　　处：《医药前沿》2020年第2期5-6,共2页Journal of Frontiers of Medicine

基　　金：广西医药卫生自筹经费科研课题(合同编号:Z20190615);桂林市科学研究与技术开发计划项目(合同编号:20190218-5-11)。

摘　　要：鼻咽癌是一种临床常见恶性肿瘤,起源于鼻咽黏膜。由EBV(Epstein-Barr病毒)感染、环境、遗传等多种因素所致。鼻咽癌具有恶性程度高、易复发、易转移、治疗难度大等特点。放化疗是临床治疗鼻咽癌的主要手段,但此种治疗模式并发症发生率、复发率均较高,患者耐受性较差。近年来,血管生成靶向治疗在鼻咽癌治疗发展迅速,具有低毒、高效、靶向性高等特点,本文主要针对鼻咽癌血管生成靶向治疗展开综述。Nasopharyngeal carcinoma is a common clinical malignant tumor that originates from the nasopharyngeal mucosa.It is caused by EBV(Epstein-Barr virus)infection,environment,genetics and other factors.Nasopharyngeal carcinoma has the characteristics of high malignancy,easy recurrence,easy metastasis,and difficult treatment.Chemoradiotherapy is the main method for clinical treatment of nasopharyngeal carcinoma,but the complication rate and recurrence rate of this treatment mode are high,and the patient is poorly tolerated.In recent years,angiogenesis-targeted therapy has developed rapidly in the treatment of nasopharyngeal carcinoma,and has the characteristics of low toxicity,high efficiency,and high targeting.This article mainly reviews the angiogenesis-targeted therapy for nasopharyngeal carcinoma.

关 键 词：血管生成 鼻咽癌 靶向治疗 

分 类 号：R730.5[医药卫生—肿瘤]